Article

Prerolled IOL appropriate option for high-risk uveitic eyes

Norfolk, VA-The CV232 Memory- Lens (Ciba Vision) is an appropriatechoice for IOL implantation after cataract surgery in patients with intraocularinflammation, said John D. Sheppard, MD, MMSc, professor of ophthalmology,microbiology, and molecular cell biology, Eastern Virginia Medical School,Norfolk.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
Steven R. Sarkisian, Jr., MD, ABO, speaks about glaucoma at the 2025 ASCRS annual meeting
Related Content
Resident surgeons perform ISBCS with similar safety and accuracy as consultants
June 13th 2025

Resident surgeons perform ISBCS with similar safety and accuracy as consultants

3 Things You Should Know About the GA Pipeline
June 4th 2025

3 Things You Should Know About Interventional Glaucoma Comanagement

FDA approves prednisolone acetate ophthalmic suspension for treating steroid-responsive ocular inflammation
June 12th 2025

FDA approves prednisolone acetate ophthalmic suspension for treating steroid-responsive ocular inflammation

Patient-Centered Treatment Strategies in the Management of nAMD and DME
May 30th 2025

Patient-Centered Treatment Strategies in the Management of nAMD and DME

Formosa Pharmaceuticals grants Harrow US commercial rights to clobetasol propionate ophthalmic suspension 0.05% (BYQLOVI), terminates deal with Eyenovia
June 12th 2025

Formosa Pharmaceuticals grants Harrow US commercial rights to clobetasol propionate ophthalmic suspension 0.05% (BYQLOVI), terminates deal with Eyenovia

Qlaris Bio announces development of QLS-111-FDC
June 12th 2025

Qlaris Bio announces development of QLS-111-FDC

© 2025 MJH Life Sciences

All rights reserved.